Zacks Investment Research on MSN
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $0.79 per share a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback